BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

@article{Nishitomi2006BACE1IR,
  title={BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.},
  author={Kouhei Nishitomi and Gaku Sakaguchi and Yuko Horikoshi and Audrey J. Gray and Masahiro Maeda and Chiho Hirata-Fukae and Amanda G. Becker and Motoko Hosono and Isako Sakaguchi and S. Sakura Minami and Yoshihiro Nakajima and Hui-fang Li and Chie Takeyama and Tsuyoshi Kihara and Akinobu Ota and Philip Chuen Yung Wong and Paul S. Aisen and Akira Kato and Noriaki Kinoshita and Yasuji Matsuoka},
  journal={Journal of neurochemistry},
  year={2006},
  volume={99 6},
  pages={1555-63}
}
Accumulation of amyloid beta peptide (Abeta) in brain is a hallmark of Alzheimer's disease (AD). Inhibition of beta-site amyloid precursor protein (APP)-cleaving enzyme-1 (BACE1), the enzyme that initiates Abeta production, and other Abeta-lowering strategies are commonly tested in transgenic mice overexpressing mutant APP. However, sporadic AD cases, which represent the majority of AD patients, are free from the mutation and do not necessarily have overproduction of APP. In addition, the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

Y. Luo, B. Bolon, +6 authors M. Citron
Neurobiol. Dis • 2003
View 3 Excerpts
Highly Influenced

The development of anti-amyloid therapy for Alzheimer’s disease: from secretase modulators to polymerisation inhibitors

P S.Aisen
CNS. Drugs • 2005

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.

Biochemical and biophysical research communications • 2004
View 9 Excerpts

Similar Papers

Loading similar papers…